Colgate-Palmolive Company (CL) $91.47
Colgate-Palmolive is currently wrestling with a technical crossroads as it retreats nearly 8% from its 52-week high, leaving investors to wonder if this is a discounted entry or a falling knife ahead of July 31 earnings.
52-wk High $99.33
📌 Investment Snapshot
- Current price of $91.47 trades at a steep 35.3x P/E multiple.
- Q1 2026 revenue hit $5.32B with EPS of $0.81, showing steady top-line growth.
- Institutional backing remains massive with Blackrock and Vanguard holding over 120M shares combined.
- Mean analyst target of $96.60 suggests limited immediate upside of 5.6%.
⏳ WAIT
The stock is currently sandwiched between two bearish Fair Value Gaps and its SMA50 support. High valuation and upcoming earnings on July 31 create a high-variance environment for new capital.
| 📍 Entry Zone | $88.21 or below | 🛑 Stop-Loss | $84.10 |
| 📋 Adjust If | Q2 earnings show operating margin compression below 20%. | ||
The Investment Case — Why Now?
Over the last 90 days, Colgate has transitioned from a momentum darling to a defensive play under pressure. While the 10.1% three-month return looks healthy, the recent 7.9% drawdown from the high reveals a cooling sentiment as the 10Y Treasury yield remains elevated at 4.55%.
The primary risk centers on the 35.3x P/E ratio, which sits significantly higher than the historical 5-year average of 24x. With free cash flow at $0.6B, the company must prove that its premium pricing power can offset rising raw material costs in the upcoming quarterly report.
Does the current 2.33% dividend yield provide enough of a safety net if the stock retests its SMA200 at $84.65?
🤔 Does the current 2.33% dividend yield provide enough of a safety net if the stock retests its SMA200 at $84.65?
🏢 Company Overview
| Detail | Value |
|---|---|
| Sector | Consumer Defensive |
| Industry | Household & Personal Products |
| Dividend Yield | 2.33% |
| Short Interest | 2.4% |
Open chart on TradingView →
📈 Price Action & Technicals
Inside VA
Sell-side Sweep at $93.08 on 2026-07-07
The stock is currently hovering just above its SMA50 of $89.90, which serves as the first line of institutional defense. A breach here likely triggers a slide toward the SMA200 at $84.65, where long-term buyers typically re-emerge.
RSI at 48.9 confirms a total lack of directional conviction, while the MACD signal line remains above the histogram, warning of a potential bearish crossover. The ADX at 25.2 indicates a trend is forming, but the -DI leading the +DI suggests that trend is currently skewed to the downside.
Price action is currently trapped below the Anchored VWAP of $85.57 from the November lows, suggesting that the average buyer from that period is still in profit but feeling the squeeze. The Volume Profile Point of Control (POC) at $84.17 remains the ultimate gravitational pull if current support fails.
Recent liquidity sweeps at $93.08 and $92.10 indicate that sellers are aggressively defending the overhead resistance levels. These ‘stop hunts’ suggest that institutional appetite for a breakout is currently low.
Historically, when CL trades in the middle of its Bollinger Bands with a volume ratio below 0.70x, it precedes a period of consolidation rather than a violent breakout. Expect sideways churn until the July 31 earnings catalyst provides a fresh narrative.
⚖ Peer P/E Comparison
| Ticker | Company | P/E (TTM) |
|---|---|---|
| CL | Colgate-Palmolive | 35.3x |
| PG | Procter & Gamble | 26.5x |
| KMB | Kimberly-Clark | 22.1x |
| SPY | S&P 500 Avg | 21.4x |
💰 Earnings Deep Dive
| Period | Revenue | EPS | YoY |
|---|---|---|---|
| 2026-03-31 | $5.32B | $0.81 | +4.1% |
| 2025-12-31 | $5.23B | $-0.05 | +1.9% |
| 2025-09-30 | $5.13B | $0.91 | +3.2% |
| 2025-06-30 | $5.11B | $0.92 | +2.8% |
Latest quarterly free cash flow stands at $0.6B, supporting a $0.3B buyback program that provides a modest floor for the share price.
Revenue has shown consistent incremental growth over the last four quarters, climbing from $5.11B to $5.32B. However, the EPS volatility in late 2025 remains a point of concern for value-oriented investors.
🚀 Growth Drivers — What Moves the Stock
- Pet Nutrition Expansion 🟢 Upside Surprise — Hill’s Pet Nutrition continues to outpace oral care growth, contributing significantly to high-margin revenue streams.
- Emerging Market Pricing 🟡 Priced In — Aggressive price hikes in Latin America and Asia are currently offsetting volume declines in mature markets.
🤔 Can Hill’s Pet Nutrition continue to carry the valuation if the core oral care segment remains stagnant?
🏦 Smart Money & Institutional Positioning
13F Holdings
| Institution | Shares (K) |
|---|---|
| Blackrock Inc. | 72,643 |
| Vanguard Capital Management LLC | 52,219 |
| State Street Corporation | 47,719 |
Holdings reflect most recent 13F (45-day lag).
Insider Transactions
| Name | Title | Date | Type | Shares |
|---|---|---|---|---|
| NEWMAN BRIAN | Director | 2026-07-01 | Purchase | 209 |
| MALCOLM GREGORY | Officer | 2026-05-15 | Purchase | 2300 |
Short Interest
| Short % Float | Days to Cover |
|---|---|
| 2.4% | 3.0 |
⚠ Key Risk Factors
~$5B market cap
~$0.15 EPS impact
🎯 Guidance & Wall Street View
Management has signaled a focus on ‘profitable volume growth’ for the remainder of 2026, though specific numerical guidance for Q3 remains under wraps.
| High Target | Mean Target | Low Target | Analysts | Consensus |
|---|---|---|---|---|
| $110.00 | $96.60 | $80.00 | 20 | Buy |
| Firm | Rating | Target | Date | Action |
|---|---|---|---|---|
| Citigroup | Buy | $102.00 | 2026-07-14 | Maintained |
| Wells Fargo | Equal-Weight | $92.00 | 2026-07-08 | Maintained |
While the consensus remains a ‘Buy,’ the average price target of $96.60 offers less than 6% upside, suggesting analysts are becoming more cautious at these levels.
Open chart on TradingView →
📊 Bull vs Bear — Probability-Weighted Scenarios
🐂 Bull Case
- Hill’s Pet Nutrition segment sees double-digit growth.
- Successful margin expansion through supply chain optimization.
📊 Base Case
Colgate maintains steady 3-4% revenue growth and holds the $90 support level through earnings.
🐻 Bear Case
- Valuation reverts to 25x P/E mean.
- Earnings miss leads to a break of SMA200 support.
🎯 Investor Action Plan — By Profile
The risk/reward is unattractive here with price sitting below bearish FVGs. Wait for a reclaim of $93.50 or a dip to the $88.00 bullish FVG for a better entry.
Existing positions should be held as long as the SMA50 at $89.90 remains intact. Use the 2.33% dividend to wait out the current volatility.
Avoid initiating new long-term positions at a 35x P/E. Patience is required to see if the stock retests the $84.17 Point of Control.
If you’re interested in the Consumer Defensive sector, also read:
❓ Investor FAQ — People Also Ask
Q: When is the next Colgate-Palmolive earnings date?
The company is scheduled to report its next quarterly earnings on July 31, 2026.
Q: Is CL stock overvalued at $91.47?
With a P/E ratio of 35.3x, CL is trading at a significant premium to its peers like P&G and Kimberly-Clark, suggesting it may be overvalued relative to its growth rate.
Q: What are the key support levels for CL?
Key support levels to watch are the SMA50 at $89.90 and the SMA200 at $84.65.
📖 New to these terms? P/E Ratio · Free Cash Flow · Insider Signals · Stop-Loss · RSI
📊 For real-time updates and advanced charting tools,
📋 Disclaimer
This analysis is for informational purposes only and does not constitute financial advice. The author has no position in CL at the time of writing.
All active positions and their real-time performance are tracked on our Investment Log.
#CL #ColgatePalmolive #StockMarket #Investing #ConsumerDefensive #TechnicalAnalysis #WallStreet